EUVIMEDEUVIMED entdecken
Crossref

Association of bisphosphonate with bone loss and pain-related behaviour in an adjuvant-induced osteoporosis model

Norihiro Mayumi, Hiroki Wakabayashi iD, Gaku Miyamura, Akihiro Sudo

Modern Rheumatology · 2024

DOI: 10.1093/mr/road085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Norihiro Mayumi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Osteoporosis, Bone Density Conservation Agents, Disease Models, Animal, Bone Density. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Osteoporosis animal models are used extensively to determine the mechanisms of disease pathology and identify potential biological targets. The study aimed to establish a bone loss model, identify pain-related behaviour in neighbouring joints using an adjuvant-induced osteoporosis model, and examine the therapeutic effect of bisphosphonates.

Methods

Complete Freund’s adjuvant was injected subcutaneously into the back of the right foot of 8-week-old female ddY mice. Subsequently, pain, arthritis, and bone density in the right knee were monitored over time.

Results

Pain evaluation using von Frey filaments showed a significantly exacerbated knee pain threshold compared to the control group (saline administration) at 7- and 14-day intervals after complete Freund’s adjuvant administration, and bone density during the same period also significantly declined. The adjuvant-induced osteoporosis model was created similarly; alendronate 40 μg/kg was subcutaneously injected twice and vehicle once from 7 to 14 days after onset. In the alendronate administration group on the 14th day, significant improvements in bone density, arthritis, and pain threshold around the knee were observed compared to the untreated group.

Conclusions

Alendronate may contribute to pain improvement through the simultaneous effects of bone mass improvement and suppression of osteoporotic pain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisBone Density Conservation AgentsDisease Models, AnimalBone DensityAnimalsFemaleMiceAlendronateArthritis, ExperimentalDiphosphonatesFreund's AdjuvantPain

Stichwörter der Autor:innen

Osteoporosisbisphosphonatepain

Substanzen

Bone Density Conservation AgentsAlendronateDiphosphonatesFreund's Adjuvant

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan.

ORCID-Profile: Hiroki Wakabayashi

Zitieren

APA

Mayumi, N., Wakabayashi, H., Miyamura, G., & Sudo, A. (2024). Association of bisphosphonate with bone loss and pain-related behaviour in an adjuvant-induced osteoporosis model. Modern Rheumatology. https://doi.org/10.1093/mr/road085

Vancouver

Mayumi N, Wakabayashi H, Miyamura G, Sudo A. Association of bisphosphonate with bone loss and pain-related behaviour in an adjuvant-induced osteoporosis model. Modern Rheumatology. 2024. doi:10.1093/mr/road085

BibTeX
@article{Mayumi2024,
  author = {Mayumi, Norihiro and Wakabayashi, Hiroki and Miyamura, Gaku and Sudo, Akihiro},
  title = {Association of bisphosphonate with bone loss and pain-related behaviour in an adjuvant-induced osteoporosis model},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road085}
}
Kostenlos starten →